Author

B. A. Mock

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:benchmark study· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

A. Aziz· 1 shared A. C. Edwards· 1 shared A. Kumari· 1 shared A. Sanz-Moreno· 1 shared B. L. Pearson· 1 shared B. Rathkolb· 1 shared C. Georgopoulou· 1 shared C. Klumpp-Thomas· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPhysiology

A. Aziz

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Deep Phenotyping and Lifetime Trajectories Reveal Limited Effects of Longevity Regulators on the Aging Process in C57BL/6J Mice

K. Xie, H. Fuchs, E. Scifo, D. Liu, A. Aziz, J. A. Aguilar- Pimentel, O. V. Amarie, L. Becker, P. da Silva-Buttkus, J. Calzada-Wack, Y.-L. Cho, Y. Deng, A. C. Edwards, L. Garrett, C. Georgopoulou, , Schmidt-Weber

This study uses large-scale phenotyping in mice to show that longevity regulators affect age-sensitive phenotypes before detectable aging begins, rather than slowing aging rates.

bioRxiv · Mar 25, 2022Physiology

mTOR Inhibition Overcomes RSK3-mediated Resistance to BET Inhibitors in Small Cell Lung Cancer

A. Kumari, L. Gesumaria, Y.-J. Liu, V. K. Hughitt, X. Zhang, M. Ceribelli, K. M. Wilson, C. Klumpp-Thomas, L. Chen, C. McKnight, Z. Itkin, C. Thomas, B. A. Mock, D. S. Schrump, H. Chen

This study identifies mTOR inhibition as a strategy to overcome RSK3-mediated resistance to BET inhibitors in small cell lung cancer, enhancing apoptosis and antitumor efficacy.

bioRxiv · Nov 8, 2021Cancer Biology